Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.

Oncoimmunology · 2023 · PMC9828731 · PMID 36632565

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Both BC-2 and JSC-1 cells showed a trend toward increased lysis by Dara when treated with Pom compared to control treatment (supplemental Figures 5E and 5F).

also in 53,322 other papers

a small trendno p-value reported

In ATRA-treated cells, we observed a small trend toward an increase in lysis in the presence of Dara (supplemental Figures 5C and 5D).

also in 722 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.